Perspective Therapeutics (CATX) details business updates via new 8-K filing

Rhea-AI Filing Summary

Perspective Therapeutics, Inc. filed a current report to let investors know it has issued a new press release describing business updates and strategic priorities. The company states that the press release, dated January 12, 2026, is attached as an exhibit and incorporated by reference, meaning the detailed operational and strategic information is contained in that accompanying document rather than in the body of this report.

0000728387false00007283872026-01-122026-01-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33407	41-1458152
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
c/o Perspective Therapeutics, Inc. 2401 Elliott Avenue Suite 320
Seattle, Washington				98121
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 676-0900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CATX		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 12, 2026, Perspective Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") announcing certain business updates and strategic priorities for the Company. A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated January 12, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	January 12, 2026	By:	/s/ Johan (Thijs) Spoor
			Johan (Thijs) Spoor Chief Executive Officer

FAQ

What did Perspective Therapeutics, Inc. (CATX) report in this 8-K?

The company reported that it issued a press release providing certain business updates and strategic priorities, and attached that press release as an exhibit.

What is the main purpose of this Perspective Therapeutics 8-K filing?

The purpose is to formally disclose that the company released a press release with business updates and strategic priorities, and to make that press release part of the public record.

Which exhibit contains the Perspective Therapeutics (CATX) business updates?

Exhibit 99.1 contains the press release dated January 12, 2026, which includes the company’s business updates and strategic priorities.

Does this 8-K include detailed financial results for Perspective Therapeutics?

No. The filing references a press release with business updates and strategic priorities but does not present detailed financial results in the text provided.

Who signed this Perspective Therapeutics current report?

The report was signed on behalf of Perspective Therapeutics, Inc. by Johan (Thijs) Spoor, Chief Executive Officer.